Loading...
•
Mar 31
Omeros Q1 2025 Earnings Report
Omeros reported a net loss and zero revenue in Q1 2025 while advancing regulatory and financial restructuring initiatives.
Key Takeaways
Omeros Corporation posted a net loss of $33.5 million in Q1 2025 with no reported revenue. The company focused its efforts on advancing the FDA review of narsoplimab and reducing near-term debt obligations through note exchanges and equity conversions.
Reported a net loss of $33.5 million, down from $37.2 million in Q1 2024.
No revenue was recognized for the quarter as OMIDRIA royalties go directly to DRI.
FDA accepted the resubmitted BLA for narsoplimab; decision expected by September 25, 2025.
Converted and exchanged significant portions of 2026 convertible notes, reducing near-term liabilities.
Omeros
Omeros
Omeros Revenue by Segment
Revenue by Segment
OMIDRIA Royalties Revenue
CapyFin.com Forward Guidance
The company is focused on securing FDA approval for narsoplimab and raising capital to resume paused programs.
Positive Outlook
- FDA accepted narsoplimab BLA resubmission with PDUFA date set for September 25, 2025.
- European marketing authorization application for narsoplimab expected in Q2 2025.
- Convertible note exchanges reduced short-term debt from $118M to $17M.
- Clinical trials for zaltenibart in treatment-naïve PNH patients to continue.
- Phase 1b OMS527 study for cocaine use disorder funded and beginning enrollment soon.
Challenges Ahead
- No revenue reported due to OMIDRIA royalties being remitted to DRI.
- Cash and short-term investments fell by $37.7 million from the previous quarter.
- Phase 3 zaltenibart PNH program paused due to capital constraints.
- Expanded access program for narsoplimab suspended to cut costs.
- Continued operating losses with limited income from discontinued operations.